ES2681434T3 - Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero - Google Patents

Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero Download PDF

Info

Publication number
ES2681434T3
ES2681434T3 ES14762249.2T ES14762249T ES2681434T3 ES 2681434 T3 ES2681434 T3 ES 2681434T3 ES 14762249 T ES14762249 T ES 14762249T ES 2681434 T3 ES2681434 T3 ES 2681434T3
Authority
ES
Spain
Prior art keywords
vectors
rlv
factor
filtrate
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14762249.2T
Other languages
English (en)
Spanish (es)
Inventor
Guang Qu
John Fraser Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Application granted granted Critical
Publication of ES2681434T3 publication Critical patent/ES2681434T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Manufacturing & Machinery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14762249.2T 2013-03-15 2014-03-17 Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero Active ES2681434T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787818P 2013-03-15 2013-03-15
US201361787818P 2013-03-15
PCT/US2014/030370 WO2014145578A1 (en) 2013-03-15 2014-03-17 Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system

Publications (1)

Publication Number Publication Date
ES2681434T3 true ES2681434T3 (es) 2018-09-13

Family

ID=51538029

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14762249.2T Active ES2681434T3 (es) 2013-03-15 2014-03-17 Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero

Country Status (16)

Country Link
US (2) US20140323556A1 (enExample)
EP (1) EP2970920B1 (enExample)
JP (1) JP6480910B6 (enExample)
KR (1) KR102200278B1 (enExample)
CN (2) CN105378074A (enExample)
AU (1) AU2014232879B2 (enExample)
BR (1) BR112015022292A2 (enExample)
CA (1) CA2904366C (enExample)
DK (1) DK2970920T3 (enExample)
ES (1) ES2681434T3 (enExample)
IL (1) IL241058B (enExample)
MX (1) MX364690B (enExample)
PT (1) PT2970920T (enExample)
RU (1) RU2709678C2 (enExample)
WO (1) WO2014145578A1 (enExample)
ZA (1) ZA201506478B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530376A (zh) 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
TWI547782B (zh) * 2015-03-16 2016-09-01 智易科技股份有限公司 可擴充式製程系統與實現該系統的方法
IL287500B2 (en) 2015-04-21 2023-12-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
MX2018006682A (es) * 2015-12-01 2018-09-26 Spark Therapeutics Inc Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico.
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CA3019126A1 (en) * 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
AU2017249402A1 (en) 2016-04-12 2018-10-04 Artemis Biosystems, Inc. Perfusion filtration systems
CN106497882A (zh) * 2016-10-29 2017-03-15 复旦大学 同时过表达R‑spondin1和Noggin的细胞株及其构建方法和应用
EP3420076B1 (en) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP4382183A3 (en) 2017-03-06 2024-08-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
CN109251939A (zh) * 2017-07-14 2019-01-22 孙搏 Il-17g-197a慢病毒表达载体、其构建方法及慢病毒的包装测定方法
EP3754025A4 (en) * 2018-01-24 2022-01-26 Slbigen Inc. Mesenchymal stem cells expressing brain-derived neurotrophic factor and use thereof
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN111763238B (zh) * 2019-04-02 2022-07-29 普莱柯生物工程股份有限公司 一种蛋白抗原的纯化方法、制备的蛋白抗原及其应用
US12565645B2 (en) * 2019-04-11 2026-03-03 Regenxbio Inc. Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
US20220282281A1 (en) * 2019-08-05 2022-09-08 Polyplus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising triazole compounds grafted to a cationic polymer, and their applications
KR20220047635A (ko) 2019-08-23 2022-04-18 론자 워커스빌 아이엔씨. 렌티바이러스 벡터의 생산을 위한 방법 및 작제물
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
CN110938654A (zh) * 2019-12-11 2020-03-31 和元生物技术（上海）股份有限公司 一种细胞转染试剂及其应用
CN113122501B (zh) * 2019-12-30 2023-06-16 重庆精准生物技术有限公司 适合大规模临床级病毒载体制备的培养基及其应用
JP2023528776A (ja) * 2020-06-11 2023-07-06 ２セブンティ バイオ インコーポレイテッド ウイルスベクターの製造方法
EP4196596A4 (en) * 2020-08-13 2025-01-01 Tmunity Therapeutics Inc. METHOD FOR PRODUCING A CLINICAL QUALITY LENTIVIRAL VECTOR
CN112746076B (zh) * 2020-12-28 2023-05-12 中吉智药(南京)生物技术有限公司 一种密码子优化的col7a1基因及慢病毒和应用
JP2024504914A (ja) * 2020-12-29 2024-02-02 江▲蘇▼金斯瑞蓬勃生物科技有限公司 高分散性ｈｅｋ２９３ｔ細胞株及びそのスクリーニング方法
TW202309294A (zh) * 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
EP4373951A1 (en) * 2021-07-19 2024-05-29 2seventy bio, Inc. Vector manufacturing processes
CN113980916B (zh) * 2021-09-27 2024-11-05 湖南丰晖生物科技有限公司 一种慢病毒的纯化方法
CN118660958A (zh) * 2021-10-12 2024-09-17 江苏金斯瑞蓬勃生物科技有限公司 适应无血清悬浮培养的hek293细胞株及其应用
CN114990077A (zh) * 2022-08-01 2022-09-02 深圳市先康达生命科学有限公司 一种慢病毒包装与纯化方法
CN116240241A (zh) * 2022-12-30 2023-06-09 上海本导基因技术有限公司 重组慢病毒载体的纯化制备方法
IN202321021121A (enExample) * 2023-03-24 2024-04-19
KR20250172638A (ko) * 2023-04-12 2025-12-09 씨티바 바이오프로세스 알＆디 에이비 크로마토그래피 시스템, 그의 용도, 및 외피보유 또는 멤브레인성 생물학적 입자를 분리하는 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US20030157070A1 (en) * 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
JP2005523722A (ja) * 2002-04-30 2005-08-11 オンコリティクス バイオテック， インコーポレイティッド 改善されたウイルス精製方法
WO2005035743A1 (en) * 2003-10-15 2005-04-21 Vector Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
ES2608638T3 (es) * 2005-07-06 2017-04-12 Ge Healthcare Bioprocess R&D Ab Método para preparar una matriz de separación
WO2008148304A1 (en) * 2007-05-31 2008-12-11 Xiamen University Rna interference target for treating aids
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
WO2009153563A1 (en) * 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
KR20110074564A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법
KR101812813B1 (ko) * 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 ａａｖ 벡터에 대한 개선된 정제 방법
SG182490A1 (en) 2010-01-12 2012-08-30 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011097447A2 (en) * 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus

Also Published As

Publication number Publication date
JP2016512700A (ja) 2016-05-09
MX364690B (es) 2019-05-06
IL241058B (en) 2020-05-31
CA2904366A1 (en) 2014-09-18
MX2015012450A (es) 2016-04-25
JP6480910B6 (ja) 2019-04-03
RU2015144057A (ru) 2017-04-27
DK2970920T3 (en) 2018-08-06
PT2970920T (pt) 2018-07-30
AU2014232879A1 (en) 2015-09-24
IL241058A0 (en) 2015-11-30
JP6480910B2 (ja) 2019-03-13
US20170368201A1 (en) 2017-12-28
US20140323556A1 (en) 2014-10-30
KR102200278B1 (ko) 2021-01-07
RU2709678C2 (ru) 2019-12-19
HK1219978A1 (en) 2017-04-21
AU2014232879B2 (en) 2020-03-05
CA2904366C (en) 2023-07-04
ZA201506478B (en) 2021-09-29
KR20160024841A (ko) 2016-03-07
CN118256453A (zh) 2024-06-28
BR112015022292A2 (pt) 2017-07-18
EP2970920A4 (en) 2016-09-14
US10994028B2 (en) 2021-05-04
CN105378074A (zh) 2016-03-02
EP2970920B1 (en) 2018-04-25
EP2970920A1 (en) 2016-01-20
WO2014145578A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US10994028B2 (en) Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
US6958226B1 (en) Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
EP4273236A1 (en) Hek293t cell strain having high dispersibility and screening method therefor
WO2023061409A1 (zh) 适应无血清悬浮培养的hek293细胞株及其应用
WO2000015819A1 (en) Packaging cell lines for hiv-derived retroviral vector particles
US11807865B2 (en) Large commercial scale lentiviral vector production system and vectors produced thereby
JP2025020287A (ja) タンパク質製造用ベクター
HK1219978B (en) Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
HK1203360B (en) Large commercial scale lentiviral vector production system and vectors produced thereby